Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

679 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial.
Balevic SJ, Benjamin DK Jr, Powderly WG, Smith PB, Gonzalez D, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Williams D, Linas BP, Blamoun J, Javeri H, Hornik CP; ACTIV-1 IM Study Group. Balevic SJ, et al. JAMA Netw Open. 2024 Apr 1;7(4):e247615. doi: 10.1001/jamanetworkopen.2024.7615. JAMA Netw Open. 2024. PMID: 38662372 Free PMC article. Clinical Trial.
Meeting the Consultation Surge: A Nationwide Survey of Consult Volume and Mitigation Strategies in Infectious Diseases Fellowship Programs.
Mena Lora AJ, Knodle R, Borgetti S, Matt B, Osorio G, Sundareshan V, Rojas-Moreno C, Bartash R, Van Schooneveld TC, Reece R, Chow B, Prakash K, Butt S, Lastinger A. Mena Lora AJ, et al. Among authors: reece r. Open Forum Infect Dis. 2024 Mar 5;11(4):ofae123. doi: 10.1093/ofid/ofae123. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38567198 Free PMC article.
High-Volume, High-Acuity, and High-Impact Learning: Tips and Tricks for Infectious Diseases Training Programs.
Luther VP, Paras ML, Schultz S, Aziz M, Balba G, McCarty TP, Razonable RR, Reece R, Shnekendorf R, Sundareshan V, Chirch LM; Infectious Diseases Society of America Infectious Diseases Training Program Directors Committee and Working Group. Luther VP, et al. Among authors: reece r. Open Forum Infect Dis. 2024 Jan 8;11(3):ofae016. doi: 10.1093/ofid/ofae016. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38434609 Free PMC article.
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.
Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C; ACTIV-3/TICO Study Group. Aggarwal NR, et al. Clin Infect Dis. 2024 Feb 20:ciad780. doi: 10.1093/cid/ciad780. Online ahead of print. Clin Infect Dis. 2024. PMID: 38376212
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.
Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens RA, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Jensen TO, et al. J Infect Dis. 2024 Mar 14;229(3):671-679. doi: 10.1093/infdis/jiad446. J Infect Dis. 2024. PMID: 37948759 Free PMC article. Clinical Trial.
679 results